Novo Nordisk’s diabetes drug Ozempic may reduce the risk of opioid overdose, study finds
Recent research suggests that Ozempic, a diabetes treatment developed by Novo Nordisk, may play an unexpected role in reducing the risk of opioid overdose. The finding introduces a potentially game-changing approach in the ongoing battle against opioid-related deaths.
The study, which delves into the effects of semaglutide (the active ingredient in Ozempic) on opioid receptors, suggests a promising link between use of the drug and decreased opioid cravings and potentially fatal overdoses. This insight is especially significant because it opens new avenues for the application of diabetes medications in addiction treatment therapies.
Novo Nordisk’s Ozempic, best known for its role in managing type 2 diabetes by improving blood sugar levels, has shown these new benefits in early clinical tri...